Biocon Biologics Launches Nepexto®, a Biosimilar to Enbrel®, in Australia

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd, announced the launch of Nepexto®, a biosimilar to the reference product Enbrel® (Etanercept), in Australia. The launch is in partnership with Generic Health, a leading provider of high-quality generic prescription, injectable and over-the-counter medicines. Etanercept is used in the treatment of autoimmune diseases and Nepexto® has seen broad adoption across Europe since its EU marketing authorization in 2020. Biocon Biologics is strategically expanding Nepexto® into new markets worldwide following the 2022 acquisition and vertical integration of the biosimilars business globally.